S&P 500   3,840.72
DOW   31,113.15
QQQ   322.59
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.59
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.59
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.59
Log in
NASDAQ:NTUS

Natus Medical Stock Forecast, Price & News

$27.46
+0.38 (+1.40 %)
(As of 01/20/2021 11:18 AM ET)
Add
Compare
Today's Range
$27.30
Now: $27.46
$27.97
50-Day Range
$19.40
MA: $21.71
$26.19
52-Week Range
$16.38
Now: $27.46
$34.67
Volume3,139 shs
Average Volume258,203 shs
Market Capitalization$930.02 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72
Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; balance assessment systems to evaluate patients with balance disorders; head-cooling products for the treatment of brain injury in newborns; and incubators to control the newborn's environment. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, and governmental agencies. The company was founded in 1987 and is headquartered in Pleasanton, California.

MarketRank

Overall MarketRank

1.09 out of 5 stars

Medical Sector

915th out of 1,928 stocks

Electromedical Equipment Industry

24th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTUS
CUSIPN/A
CIKN/A
Phone925-223-6700
Employees1,484

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$495.52 million
Cash Flow$2.34 per share
Book Value$12.21 per share

Profitability

Net Income$-15,670,000.00

Miscellaneous

Market Cap$930.02 million
Next Earnings Date2/25/2021 (Confirmed)
OptionableOptionable
$27.46
+0.38 (+1.40 %)
(As of 01/20/2021 11:18 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NTUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Natus Medical (NASDAQ:NTUS) Frequently Asked Questions

How has Natus Medical's stock been impacted by COVID-19 (Coronavirus)?

Natus Medical's stock was trading at $27.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NTUS stock has increased by 1.0% and is now trading at $27.44.
View which stocks have been most impacted by COVID-19
.

Is Natus Medical a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natus Medical in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Natus Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NTUS, but not buy additional shares or sell existing shares.
View analyst ratings for Natus Medical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Natus Medical?

Wall Street analysts have given Natus Medical a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Natus Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Natus Medical's next earnings date?

Natus Medical is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Natus Medical
.

How can I listen to Natus Medical's earnings call?

Natus Medical will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Natus Medical's earnings last quarter?

Natus Medical Incorporated (NASDAQ:NTUS) released its quarterly earnings data on Thursday, October, 29th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.08. The company had revenue of $102.80 million for the quarter, compared to the consensus estimate of $94.40 million. Natus Medical had a negative net margin of 4.33% and a positive return on equity of 3.87%. The company's revenue was down 16.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.36 EPS.
View Natus Medical's earnings history
.

What guidance has Natus Medical issued on next quarter's earnings?

Natus Medical issued an update on its fourth quarter earnings guidance on Friday, January, 8th. The company provided earnings per share (EPS) guidance of $0.19-0.31 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.24. The company issued revenue guidance of $118-119 million, compared to the consensus revenue estimate of $110.00 million.

Who are some of Natus Medical's key competitors?

What other stocks do shareholders of Natus Medical own?

Who are Natus Medical's key executives?

Natus Medical's management team includes the following people:
  • Mr. Jonathan A. Kennedy CPA, Pres, CEO & Director (Age 49, Pay $1.27M)
  • Mr. Benjamin Drew Davies, Exec. VP & CFO (Age 54, Pay $733.73k)
  • Dr. D. Christopher Chung, VP of Quality, Regulatory Affairs & Chief Medical Officer (Age 56, Pay $517.89k)
  • Mr. Austin F. Noll III, Exec. VP & Chief Commercial Officer (Age 53, Pay $685.2k)
  • Mr. Seán Langan, VP Global Operations
  • Mr. Ivan Pandiyan, VP of Global R&D
  • Mr. William Hill, Gen. Counsel
  • Ms. Lisa Paul, Chief People Officer & VP (Age 56)

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "NTUS."

Who are Natus Medical's major shareholders?

Natus Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirador Capital Partners LP (0.12%) and State of Alaska Department of Revenue (0.08%). Company insiders that own Natus Medical stock include Dong Chune Christopher Chung, Jonathan Kennedy and Lisa Wipperman Heine.
View institutional ownership trends for Natus Medical
.

Which institutional investors are selling Natus Medical stock?

NTUS stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Natus Medical
or view top insider-selling stocks.

Which institutional investors are buying Natus Medical stock?

NTUS stock was acquired by a variety of institutional investors in the last quarter, including Mirador Capital Partners LP.
View insider buying and selling activity for Natus Medical
or or view top insider-buying stocks.

How do I buy shares of Natus Medical?

Shares of NTUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Natus Medical's stock price today?

One share of NTUS stock can currently be purchased for approximately $27.44.

How big of a company is Natus Medical?

Natus Medical has a market capitalization of $929.34 million and generates $495.52 million in revenue each year. The company earns $-15,670,000.00 in net income (profit) each year or $1.24 on an earnings per share basis. Natus Medical employs 1,484 workers across the globe.

What is Natus Medical's official website?

The official website for Natus Medical is www.natus.com.

How can I contact Natus Medical?

Natus Medical's mailing address is 6701 KOLL CENTER PARKWAY SUITE 120, PLEASANTON CA, 94566. The company can be reached via phone at 925-223-6700 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.